Dementias Platform UK (DPUK) is a multi-million pound public-private partnership which launched in 2014. DPUK is directed by Professor John Gallacher (University of Oxford) and is supported by an executive team of ten other representatives from our academic and industry partners.
Our governance structure
A steering group of 20 senior scientists, many of whom lead projects across the platform, influence the scientific direction of the project by making recommendations to the executive team.
The Company Partner Forum (CPF) is made up of representatives from each of DPUK's industry partners. Together they apply their longstanding industry experience, advising on the development of DPUK resources so they meet the needs of those who are developing treatments.
The director and executive team, in turn, report to an MRC-appointed Oversight Board twice a year. The board oversees DPUK activity and advises on opportunities or changes for the project. Its members are UK and international experts in the field of dementia.
DPUK is supported by four international advisors, all experts in the field of dementia and neurodegenerative disease.
Our funding
Dementias Platform UK has received £53 million from the UK Medical Research Council. Each of our industry partners also makes a contribution – financial or in-kind – to enable our work. The amount of additional funding for dementia research that we have attracted can be seen in the table below.
|
£ m |
Funder and project |
Principal Investigator |
University |
Funding type |
|---|---|---|---|---|
|
16 |
MRC-industry core funding |
John Gallacher |
Cardiff |
Core |
|
37 |
MRC clinical research infrastructure: |
Paul Matthews |
Imperial College London, Oxford Oxford |
Core |
|
1 |
MRC: Imaging partnership |
Karl Herholz |
Manchester |
Supported |
|
1 |
MRC: Stem Cells partnership |
Siddharthan Chandran |
Edinburgh |
Supported |
|
0.3 |
Alzheimer's Research UK (ARUK): Imaging |
David Thomas |
University College London |
Supported |
|
2 |
Stroke Association: Vascular Risk |
Joanna Wardlaw |
Edinburgh |
Supported |
|
0.5 |
Janssen and Alzheimer's Research UK (ARUK): Synaptic Health |
James Rowe |
Cambridge |
Supported |
|
60 |
Innovative Medicines Initiative (IMI): European Prevention of Alzheimer's Dementia Consortium (EPAD) |
Craig Ritchie |
Edinburgh |
Enabled |
|
7 |
MRC National Institute for Health Research (NIHR): Deep and Frequent Phenotyping |
Simon Lovestone |
Oxford |
Enabled |
|
3.4 |
Innovative Medicines Initiative (IMI): Real World Outcomes Across the Alzheimer's Disease Spectrum (ROADS) |
John Gallacher |
Oxford |
Enabled |
|
1.1 |
MRC: UK7T partnership |
James Rowe |
Cambridge |
Enabled |
|
7 |
MRC clinical research infrastructure: UK7T |
James Rowe |
Cambridge |
Enabled |
|
0.1 |
MRC: Korea |
Chi-Hun Kim |
Oxford |
Enabled |
|
Research income generated: £83.4 m (157% of core funding)
|
||||